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Abstract
Altered transcriptional programs are a hallmark of diseases, yet how these are established is still ill-defined. PBX1 is a TALE
homeodomain protein involved in the development of different types of cancers. The estrogen receptor alpha (ERa)i s
central to the development of two-thirds of all breast cancers. Here we demonstrate that PBX1 acts as a pioneer factor and
is essential for the ERa-mediated transcriptional response driving aggressive tumors in breast cancer. Indeed, PBX1
expression correlates with ERa in primary breast tumors, and breast cancer cells depleted of PBX1 no longer proliferate
following estrogen stimulation. Profiling PBX1 recruitment and chromatin accessibility across the genome of breast cancer
cells through ChIP-seq and FAIRE-seq reveals that PBX1 is loaded and promotes chromatin openness at specific genomic
locations through its capacity to read specific epigenetic signatures. Accordingly, PBX1 guides ERa recruitment to a specific
subset of sites. Expression profiling studies demonstrate that PBX1 controls over 70% of the estrogen response. More
importantly, the PBX1-dependent transcriptional program is associated with poor-outcome in breast cancer patients.
Correspondingly, PBX1 expression alone can discriminate a priori the outcome in ERa-positive breast cancer patients. These
features are markedly different from the previously characterized ERa-associated pioneer factor FoxA1. Indeed, PBX1 is the
only pioneer factor identified to date that discriminates outcome such as metastasis in ERa-positive breast cancer patients.
Together our results reveal that PBX1 is a novel pioneer factor defining aggressive ERa-positive breast tumors, as it guides
ERa genomic activity to unique genomic regions promoting a transcriptional program favorable to breast cancer
progression.
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Introduction
The implementation of transcriptional programs is central to
the commitment of pluripotent cells occurring throughout
development [1,2]. Likewise, diseases commonly arise from altered
transcriptional programs. This requires active reprogramming
characterized by chromatin remodeling and altered epigenetic
signature at lineage-specific functional genomic elements [2–5].
The estrogen receptor alpha (ERa) is a nuclear receptor central to
breast cancer development. Upon estrogen stimulation, it binds at
thousand of genomic loci defining its cistrome to promote a pro-
proliferative transcriptional program [6–9]. Its genomic actions
are in part dependent on the pioneer factor FoxA1
[6,7,8,10,11,12,13,14]. Pioneer factors are an emerging class of
DNA binding proteins. They play a central role in defining
transcriptional programs as they can integrate and remodel
condensed chromatin rendering it competent for transcription
factor binding [6,15,16,17,18,19]. Their recruitment to the
chromatin is sequence specific and can be facilitated by an
epigenetic signature dependent on histone methylation [6,20].
PBX1 (Pre-B-cell leukemia homeobox 1) is a member of the
Three Amino acid Loop Extension (TALE)-class homeodomain
family required for diverse developmental processes including
hematopoiesis [21], skeleton patterning [22], pancreas [23], and
urogenital systems organogenesis [24,25]. While it is best known as
an oncoprotein when fused to E2A in pre-B-cell leukemia [26], it
also contributes to prostate, ovarian and esophageal cancer [27–
30]. It is also highly expressed in breast cancer [31]. PBX1 is a
cofactor for homeobox (HOX) transcription factors as it increases
their affinity and specificity to chromatin [32,33]. However, recent
interactome studies have revealed that 12% of PBX1 putative
partners are non-homeodomain transcription factors [34,35]. In
agreement, PBX1 modulates the transcriptional activity of nuclear
receptors such as the thyroid and glucocorticoid receptors and was
recently proposed to act as a pioneer factor for the bHLH factor
MyoD [36–38]. However, the contribution of PBX1 to chromatin
structure and epigenetic signatures regulating transcription in
ERa-positive breast cancer cells is unknown. In the present study,
we have investigated the pioneer function of PBX1 towards ERa
genomic activity in breast cancer.
Results
PBX1 is essential to the estrogen response in
ERa-positive breast cancer cells
Condensed chromatin constitutes a barrier for the recruitment
of transcription factors to the DNA. FoxA1 binding at specific
genomic regions allows for chromatin remodeling favorable to
PLoS Genetics | www.plosgenetics.org 1 November 2011 | Volume 7 | Issue 11 | e1002368ERa recruitment at a subset of its cistrome [6,8,13,19,39].
However, ERa is recruited to thousands of FoxA1-independent
sites across the genome [6]. To identify candidate pioneer factors
guiding ERa recruitment to the chromatin at these sites we
performed seeded motif analyzes using the Cistrome-web
application (http://cistrome.dfci.harvard.edu/ap/). This revealed
that over 85% of the ERa cistrome harbors the DNA motif
recognized by PBX1 (Figure 1A and 1B). Noteworthy, the
presence of the PBX1 motif in ERa binding sites was significantly
different from another similar size cistrome (androgen receptor
(AR) cistrome from LNCaP cells, p,1e-99) (Figure S1A).
Analyzing expression profiles from the NCI60 panel of cancer
cells compiled on bioGPS (http://biogps.gnf.org) [40,41] reveals
that PBX1 is significantly co-expressed with ERa (co-expression
coefficient 0.7784 using probe 205253_at) (Table S1). This was
also revealed by comparing PBX1 mRNA expression across 47
distinct ERa-positive and negative breast cancer cells (p=8.98e-7)
(Figure 1C). ERa mRNA expression was also significantly
correlated with ERa-histological status of breast cancer cells
(p=1.71e-8) (Figure 1C). These results are further supported by
RT-qPCR, immunofluorescence and western blot analyzes in
ERa-positive MCF7 and ERa-negative MDA-MB231 breast
cancer cells demonstrating co-expression of ERa and PBX1 at
the mRNA and protein level (Figure 1D). PBX1 is one of four
PBX family members [33]. RT-qPCR against other PBX1 genes
demonstrates that PBX1 is the predominant family member
expressed in ERa-positive breast cancer cells (Figure S1B).
Analyses of 41 independent breast cancer expression profile
studies, such as van de Vijver study, demonstrate that PBX1 and
ERa are also co-expressed in primary breast tumors (p=2.72e-13
for the van De Vijver study and p#1e-4 for all other studies)
(Figure 1E) [42]. The correlation between ERa mRNA expression
and ERa-histological status is also reported for the van de Vijver
study (p=2.27e-74) (Figure 1E).
To address the functional relation between PBX1 and ERa we
assessed the role of PBX1 on estrogen-induced growth in the ERa-
positive MCF7 breast cancer cells. PBX1 mRNA and protein
levels were significantly depleted (,70%) in MCF7 breast cancer
cells transfected with one of two independent siRNA against PBX1
(Figure 2A and 2B). In agreement with a role for PBX1 in breast
cancer [27], PBX1 depletion completely prevented the estrogen-
induced proliferation of MCF7 breast cancer cells (Figure 2C and
S2A-B). Importantly, PBX1 depletion in MCF7 breast cancer cells
did not affect ERa or FoxA1 expression both at the mRNA and
protein level (Figure 2D). Overall these results support a functional
role for PBX1 in mediating the response to estrogen in ERa-
positive breast cancer.
PBX1 marks functional ERa binding sites
Estrogen signaling involves ERa activation and subsequent
recruitment to the chromatin. Pioneer factors can therefore be
identified through their role at the chromatin prior to estrogen
treatment. Immunofluorescence assays against PBX1 in MCF7
breast cancer cells deprived of estrogen demonstrate its localiza-
tion to the nucleus (Figure 3A). While PBX1 and FoxA1 have a
similar nuclear distribution, confocal immunofluorescence analysis
against FoxA1 reveals that it only partially overlaps with PBX1
(Figure 3A and Figure S3A and S3B). To demonstrate that PBX1
occupies the chromatin in MCF7 breast cancer cells we performed
a ChIP-seq assay in cells maintained in full media. This identified
24254 high-confidence PBX1 sites (p#1e-5) predominantly
localized a distant regulatory elements (Figure 3B and Figures
S4A and S4B, S5, S6, S7, S8). Directed ChIP-qPCR assays on 37
randomly selected PBX1 bound sites identified by ChIP-seq
demonstrates that it is loaded to the chromatin in absence of
estrogen (Figure S4B). Approximately 50% of the estrogen-
induced ERa cistrome overlaps with PBX1 bound sites
(Figure 3B). A significant overlap between ERa and PBX1 is also
observed for all publically available ERa cistromes (Figure S9)
[6,7,9,43,44,45,46,47,48,49,50,51]. FoxA1 is loaded to the
majority of these sites (Figure 3B). In fact, ChIP-reChIP assays
in MCF7 breast cancer cells maintained in estrogen free media
demonstrates that both pioneer factors co-localize on the
chromatin at shared sites (Figure S11). Importantly, over 37% of
the FoxA1-independent ERa binding sites overlap with PBX1
(Figure 3B). Expression profile analysis in MCF7 breast cancer
depleted of PBX1 reveals that a 71% of estrogen-induced target
genes are dependent on PBX1 (Table S2 and Figure S12).
Importantly, the estrogen signature identified by this expression
profile was highly enriched for genes defining ERa-positive
primary breast tumors (p=5.75e-10) [52].
To assess the relation between genome-wide binding and
expression profiles we cross-examined the estrogen responsive
gene lists (all estrogen responsive genes and PBX1-dependent
estrogen responsive genes) defined in MCF7 breast cancer cells
against the binding profiles for ERa, PBX1 and FoxA1. This was
accomplished by determining the number of estrogen responsive
genes (all or PBX1-dependent) harboring at least one binding sites
shared or unique to a given factor within 620 kb from their
transcription start site (TSS). This was repeated for the null list
consisting of all genes from the refseq gene list not regulated upon
estrogen stimulation in MCF7 breast cancer cells. The ratio of
estrogen responsive genes associated with binding events within
620 kb of their TSS over the number of genes from the null list
associated with binding events within 620 kb of their TSS was
then plotted in a radar format. Estrogen target genes were
significantly associated with PBX1-ERa shared sites (7% of total
estrogen-responsive genes) and PBX1-FoxA1-ERa shared sites
(12% of total estrogen-responsive genes) (blue line, Figure 3C).
FoxA1-ERa shared sites did not preferentially associate with
estrogen regulated genes (Figure 3C). Remarkably, PBX1-
dependent estrogen target genes were specifically associated with
PBX1 unique and PBX1-ERa shared sites (red line, Figure 3C).
This was validated through RT-qPCR against estrogen target
genes dependent on PBX1, FoxA1 or both. Indeed, PBX1
Author Summary
Approximately two-thirds of breast cancers depend on the
estrogen receptor alpha (ERa) for their growth. Its capacity
to act as a transcription factor binding DNA following
estrogen stimulation is central to promote a pro-tumori-
genic transcriptional response. Importantly, different
classes of ERa-positive breast tumors can be discriminated
based on outcome. However, the underlying mechanisms
driving these differences are unknown. Here we demon-
strate that PBX1 acts as a pioneer factor recognizing a
specific epigenetic modification to remodel chromatin and
guide ERa genomic activity. This translates in a specific
transcriptional program associated with poor-outcome in
breast cancer patients. Even more, PBX1 expression alone
is sufficient to identify a priori ERa-positive breast cancer
patients at risk of developing metastasis. Overall, this study
defines the mechanisms dependent on the pioneer factor
PBX1 that drives an aggressive response in a subset of ERa-
positive breast cancers. These features highlight the
uniqueness of PBX1 and demonstrate its potential
prognostic value.
PBX1 Guides ERa Signaling in Breast Cancer
PLoS Genetics | www.plosgenetics.org 2 November 2011 | Volume 7 | Issue 11 | e1002368Figure 1. PBX1 correlates with ERa. (A) Motif/sequence logo representation of the PBX1 matrix (Transfac: M01017). (B) The proportion of ERa
binding sites harboring the PBX1 matrix (Transfac: M01017) is presented taking into account the overlap of ERa binding sites with FoxA1 binding
sites. Percentages are calculated based on the 5782 ERa binding sites. (C) Co-expression of PBX1 and ERa mRNA transcripts is demonstrated across 47
distinct breast cancer cell lines separated based on their ERa-histological status. The p value revealing significant correlation between ERa-
histological status and mRNA expression for ERa and PBX1 is presented. (D) Both mRNA (left panel) and protein (derived from immuno-fluorescence
or western blot, right and bottom panel respectively) levels for PBX1 correlate with ERa expression status when assessed in ERa-positive (MCF7) and
ERa–negative (MDA-MB231) breast cancer cells (average from three independent probes against PBX1 is presented for the mRNA expression analysis
provided by bioGPS.org). (E) PBX1 and ERa are co-expressed in primary breast tumors. Expression profiles from primary breast tumors reveals that
PBX1 mRNA levels are correlated with ERa-histological status and ERa mRNA expression in primary breast tumors (meta-analysis conducted using
Oncomine). (*,0.05, **,0.01***, ,0.001 p value).
doi:10.1371/journal.pgen.1002368.g001
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dependent estrogen target genes in MCF7 breast cancer (Figure 3D
and Figure S13). Conversely, FoxA1 silencing impacted only the
regulation of shared and FoxA1-dependent estrogen target genes
(Figure 3D and Figure S13). Collectively, these data support the
notion that PBX1 is required to regulate a specific subset of
estrogen responsive genes. Moreover, they suggest that PBX1 is
required for the implementation of an estrogen regulated
transcriptional program distinct from FoxA1.
PBX1 controls ERa genomics activity
ERa-dependent transcriptional response is dependent on its
recruitment to the chromatin following estrogen stimulation. To
test if PBX1 directly impacts ERa genomic activity we first
assessed PBX1 occupancy through ChIP-qPCR assays at known
ERa binding sites in MCF7 breast cancer cells treated or not with
estrogen. Focusing on both FoxA1-dependent and independent
ERa binding sites overlapping with PBX1 (Figure S4C), our
results demonstrate that PBX1 is pre-loaded on the chromatin
prior to estrogen treatment and remains bound following estrogen
treatment (Figure 4A). These sites were chosen from our genome-
wide analysis since they are proximal to genes fundamental for
breast cancer proliferation and ERa biology. For instance, Myc,
CCND1, FOS and EGR3 are well-studied ERa targets promoting
breast cancer growth and progression [53,54,55]. TFF1 (also
known as PS2) is the prototypical estrogen target gene [56].
Sequential ChIP assays (ChIP-reChIP) against ERa and PBX1 in
both estrogen treated and untreated MCF7 breast cancer cells
demonstrates that both factors co-occupy the same sites following
ERa recruitment (Figure 4B).
Figure 2. PBX1 is required for the estrogen response in MCF7 cells. (A) PBX1 depletion via siRNA effectively reduces its mRNA and (B) protein
levels. (C) MCF7 breast cancer cells depleted of PBX1 fail to proliferate in response to estrogen/17b-estradiol (E2) stimulation compared to control
treatment (O). (D) PBX1 silencing does not alter ERa or FoxA1 mRNA (histogram) or protein levels (Western Blot, WB). (*,0.05, **,0.01***, ,0.001 p
value).
doi:10.1371/journal.pgen.1002368.g002
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PLoS Genetics | www.plosgenetics.org 4 November 2011 | Volume 7 | Issue 11 | e1002368Figure 3. PBX1 marks functional ERa bindings. (A) Confocal immunofluorescence analysis in MCF7 cells cultured in absence of estrogen/17b-
estradiol (E2) reveals that PBX1 is localized in the nucleus of MCF7 breast cancer cells and partially overlap with the pioneer factor FoxA1. (B) Venn
diagram of PBX1 (Full media), ERa (after estrogen stimulation) and FoxA1 (full media) cistromes reveal their significant overlap on the chromatin. (C) A
comparison between E2 responsive genes (all or PBX1-dependent) and the unique versus shared ERa, FoxA1 and PBX1 binding sites defined in
Figure 3B was performed by normalizing the number of responsive genes with at least one unique or shared binding site a given factor within
620 kb of their transcription start site (TSS) to the number of unresponsive genes with at least one binding sites from the same type of site within
620 kb of their TSS. The values for all E2 responsive genes (blue line) and PBX1-dependent E2 responsive genes (red line) were plotted in a radar
format (1, dark grey area, 1–2 light grey area, .2 white area, ticks are 0.5 increments). (*,0.01, **,0.001***, ,0.00001 p value). (D) RT-qPCR against
E2 target genes associated with PBX1-FoxA1-ERa, PBX1-ERa or FoxA1-ERa binding sites based on Figure 3C was performed in MCF7 breast cancer
cells depleted of PBX1 (siPBX1) or Foxa1 (siFoxA1). A control siRNA (siCTRL) was used for comparison.
doi:10.1371/journal.pgen.1002368.g003
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cancer cells demonstrate that ERa recruitment following estrogen
treatment is dependent on PBX1 (Figure 4C). Importantly, ERa
recruitment is disrupted selectively at sites with pre-loaded PBX1
but not at PBX1-independent sites (Figure 4D and Figure S4D) thus
ruling out the possibility of a widespread non-specific impact on
ERa ability to bind DNA in cells depleted of PBX1. Overall these
results demonstrate that PBX1 can occupy the chromatin prior to
ERa recruitment and is required for its genomic activity driving
estrogen target gene expression. This is in agreement with a role for
PBX1 as a novel pioneer factor in breast cancer.
PBX1 actively impart open chromatin structure at
regulatory elements
Chromatin structure inherently represents an obstacle for
transcription factor activity. Through their ability to integrate
and open condensed chromatin, pioneer factors act as molecular
beacons for other transcription factors. Using FAIRE (Formalde-
hyde Assisted Isolation of Regulatory Elements) assays [39,57] to
measure chromatin condensation/openness prior to estrogen
stimulation, we demonstrate that PBX1 acts as a pioneer factor.
Indeed, genome-wide FAIRE-seq assays in MCF7 breast cancer
cells [44] reveals that PBX1 occupied chromatin is already highly
accessible (Figure 5A and Figure S14). Interestingly, the
pioneering activity of PBX1 and FoxA1 is synergistic on shared
sites (Figure 5A). Sites only bound by FoxA1 are the least
accessible (Figure 5A). Comparing FAIRE signal in estrogen
starved MCF7 breast cancer cells depleted or not of PBX1
through siRNA revealed a significant decrease in chromatin
openness in PBX1-depleted compared to control cells at the
majority of tested sites (Figure 5B). In agreement, we demonstrate
that PBX1 depletion in MCF7 breast cancer cells seen at the
Figure 4. PBX1 is located in the nucleus and mediates ERa genomics activity. (A) PBX1 occupies ERa genomic targets prior to its recruitment
followingestrogen/17b-estradiol(E2)stimulationcomparedtocontroltreatedcells(O).Similarly,PBX1remainsboundtothechromatinafterE2treatment
in MCF7 breast cancer cells as determined by ChIP-qPCR. (B) ChIP-reChIP assays reveal that PBX1 and ERa co-occupy the same genomic regions upon E2
stimulation. In addition to a negative control site, matched IgG were used as a negative control in the reChIP assay. (C) PBX1 silencing (siPBX1) abrogates
ERa recruitment at regulatory elements in MCF7 breast cancer cells compared to control (siCTRL). Values are calculated as a ratio between untreated and
E2 treated relative fold enrichment definedby ChIP-qPCR. (D) ChIP-qPCR against ERa atPBX1-independent sites demonstrates that ERa recruitment is not
disrupted at these sites upon PBX1 silencing. Values are calculated as a ratio between untreated and E2 treated relative fold enrichment.
doi:10.1371/journal.pgen.1002368.g004
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PLoS Genetics | www.plosgenetics.org 6 November 2011 | Volume 7 | Issue 11 | e1002368Figure 5. PBX1 is an independent pioneer factor required for chromatin openness whose binding is favored by H3K4me2. (A)
Genome wide FAIRE profiles (FAIRE-seq) from MCF7 breast cancer cells maintained in estrogen-free media demonstrate that PBX1 alone or in
combination with FoxA1 correlates with open chromatin. (B) Depletion of PBX1 (siPBX1) in MCF7 breast cancer cells maintained in estrogen-free
media significantly reduces chromatin openness at PBX1 binding sites compared to control siRNA transfected cells (siCTRL) as measured by FAIRE-
qPCR. (C) FoxA1 silencing (siFoxA1) does not alter PBX1 binding to the chromatin compared to control (siCTRL) in MCF7 breast cancer cells
maintained in estrogen-free media. (D) PBX1 silencing in MCF7 breast cancer cells maintained in estrogen-free media does not affect FoxA1 binding
to the chromatin compared to control. (E) Venn diagram of PBX1 and FoxA1 cistromes defined in full-media as well as H3K4me2 epigenome defined
in MCF7 breast cancer cells maintained in estrogen-free media reveals their overlap. (F) Over-expression of the H3K4me2 demethylases KDM1 in
MCF7 breast cancer cells maintained in estrogen-free media results in a significant reduction of PBX1 binding to the chromatin compared to the
empty vector control (CTRL). (*,0.05, **,0.01***, ,0.001 p value).
doi:10.1371/journal.pgen.1002368.g005
PBX1 Guides ERa Signaling in Breast Cancer
PLoS Genetics | www.plosgenetics.org 7 November 2011 | Volume 7 | Issue 11 | e1002368mRNA and protein level (Figure 2A and 2B) also significantly
decreases its occupancy on the chromatin (Figure S10B). These
results suggest that PBX1 plays a central role in increasing
chromatin accessibility essential for transcription factor recruit-
ment further supporting its role as a pioneer factor in breast cancer
cells.
Immunofluorescence, ChIP-seq assays and ChIP-reChIP
against PBX1 and FoxA1 suggests that they co-occupy genomic
regions in MCF7 breast cancer cells (Figure 3A and 3B, Figures
S3A and S3B, S9, S10, and S11). To determine if they collaborate
with each other at these genomic regions or if they are part of a
common complex we profiled FoxA1 binding following PBX1
depletion in estrogen starved MCF7 breast cancer cells. In
agreement with both pioneer factors acting independently of each
other, FoxA1 depletion did not alter PBX1 binding to the
chromatin (Figure 5C). Similarly, PBX1 depletion did not affect
FoxA1 recruitment to the chromatin (Figure 5D). Overall, these
results reveal that PBX1 acts as a pioneer factor guiding ERa
genomic activity independently of FoxA1 in breast cancer.
Covalent modifications are a main staple of epigenetic
regulation. Previous reports have demonstrated that methylation
of histone H3 on lysine 4 (H3K4me) can define functional
regulatory element [58–61]. Furthermore, cell type-specific
distribution of the mono and di-methylated H3K4 (H3K4me1
and me2) epigenetic modifications are central to cell type-specific
transcriptional responses [6,59,60]. In cancer cells, depletion of
H3K4me2 interferes with FoxA1 binding to chromatin [6,39].
However, the relationship between FoxA1 and H3K4me2 may
not be unidirectional, recent evidence suggesting that FoxA1 can
favor H3K4me2 deposition [62]. Genome-wide analysis revealed
that H3K4me2 is present on approximately 50% of the PBX1
cistrome (Figure 5E). A similar proportion of FoxA1 cistrome
overlaps with the H3K4me2 distribution in MCF7 breast cancer
cells (Figure 5E). To test if H3K4me2 favors PBX1 binding to the
chromatin we overexpressed H3K4me2 demethylase KDM1
(LSD1/BCH110) and determined PBX1 chromatin occupancy
through ChIP-qPCR assays. KDM1 over-expression led to a
significant reduction of bound PBX1 in estrogen starved MCF7
cells (Figure 5F). In contrast, PBX1 depletion had no effect on
H3K4me2 levels and did not affect KDM1 expression (Figure
S15A and S15B). Hence, similarly to FoxA1, the H3K4me2
epigenetic signature favors PBX1 binding.
PBX1 is a novel prognostic factor that discriminated ERa
breast cancer outcomes
ERa drives proliferation in over 70% of all breast cancers.
Accordingly it serves both as a therapeutic target and prognostic
factor [63]. In addition, ERa is to date the most exploited marker
in the clinic and generally associates with good outcome [64].
FoxA1 does not appear to provide any additional power to
discriminate breast cancer subtypes in comparison to ERa
profiling [65–67]. To assess the prognostic value of PBX1 in
breast cancer we performed a meta-analysis using breast tumor
expression studies with follow-up data available through Onco-
mine (Compendia Bioscience, Ann Arbor, MI). We differentiated
breast cancer patients according to high (top 10%) or low (bottom
10%) PBX1 mRNA levels and then generated Kaplan-Meier
curves according to the metastasis-free survival status of breast
cancer patients. In addition, we independently generated Kaplan-
Meier curves using the KMplot web application [68]. Results
derived from this analysis performed against FoxA1 confirmed
previous reports limiting its prognostic value to identify ERa-
positive breast cancers within all breast cancer subtypes. PBX1
expression did not discriminate outcome in these same patients
(Figure 6A and 6B and Figure S16A and S16B) Interestingly, while
FoxA1 mRNA levels where predictive of ERa status, PBX1 levels
were evenly distributed in the ERa-positive breast cancer
subgroups or all-cases (Figure S17). By focusing our analysis on
ERa-positive breast cancer patients (as defined by pathological
staining) we revealed the prognostic value of PBX1. Indeed, ERa-
positive breast tumors with high PBX1 expression levels are
associated with a reduced metastasis-free survival compared to
ERa-positive breast tumors with low PBX1 expression (p,0.002)
(Figure 6C and Figure S16C and S16D). FoxA1 expression could
not stratify metastasis-free survival within ERa-positive breast
cancer patients (Figure 6D and Figure S16C and S16D) in
agreement with the redundant prognostic value of FoxA1 and
ERa [67].
These results are further supported by comparing the PBX1-
dependent estrogen induced transcription (Table S2 and Figure
S12) against expression profiled from breast tumors using
Oncomine (Compendia Bioscience, Ann Arbor, MI). This reveals
the strong correlation between PBX1-dependent estrogen target
genes and twenty-two expression signatures typical of poor-
outcome in breast cancer patients (ex: metastasis, mortality,
recurrence and high grade) (p,0.01, O.R. .2) (Figure 6E). In
contrast, the FoxA1-dependent estrogen target genes [44] are
significantly associated with only one poor-outcome expression
signature (mortality) from breast cancer (Figure 6E). Taken
together, this suggests that PBX1 drives a very specific transcrip-
tional response underlying progression in ERa-positive breast
cancer and reveal the potential prognostic potential for PBX1
within this breast cancer subtype to predict outcome.
Discussion
Accurate regulation of complex transcriptional programs is
central to normal organ development. This is dependent on
several layers of controls including DNA sequence, epigenetic
signatures and chromatin structure. However, how these different
elements are integrated to generate lineage-specific transcriptional
programs and how they are affected in the course of disease
development is ill defined. In particular, we still misunderstand
how epigenetic signatures and chromatin structure affect the
transcriptional response to estrogen stimulation in breast cancer.
Here we demonstrate that PBX1 acts as a pioneer factor guiding
ERa genomic activity in breast cancer (Figure 7). Indeed, PBX1
translates the H3K4me2-based epigenetic signature to remodel
specific genomic domains rendering them accessible for ERa.
PBX1 was show to be crucial for histone H4 acetylation [69] and
previous reports focusing on the recruitment of MyoD and PDX1
to the chromatin in myeloid and pancreatic islet cells, respectively,
were suggestive of the pioneering role of PBX1 [36,70].
Considering that PBX1 plays a fundamental role in the
development of diverse organs [21,24,25] and contributes to
various types of cancers, namely leukemia, prostate, ovarian and
esophageal cancers [26–30], its pioneering functions are likely to
apply beyond breast cancer. Similarly, the genomic activity of a
wide-range of transcription factors including both homeodomain
(HOX, MEIS, etc) and non-homeodomain protein (MyoD, GR,
TR, etc) is promoted by PBX1 [32,33,36,37,38,71,72]. Hence,
PBX1 pioneering functions are expected to affect additional
transcriptional programs.
Finally, we reveal that PBX1 and FoxA1 can co-occupy specific
genomic regions in breast cancer cells. While co-occupancy of
specific genomic region by pioneer factors, such as PU.1 and
GATA1 has previously been reported [73], our results demon-
strates that this translates into greater chromatin accessibility.
PBX1 Guides ERa Signaling in Breast Cancer
PLoS Genetics | www.plosgenetics.org 8 November 2011 | Volume 7 | Issue 11 | e1002368Furthermore, we reveal that FoxA1-independent PBX1 bound
sites are more accessible than PBX1-independent FoxA1 sites. In
agreement, the estrogen induced transcriptional response is
preferentially associated with ERa binding at PBX1 or PBX1-
FoxA1 shared sites. This also relates to a distinct prognostic value
for FoxA1 and PBX1. Indeed, while FoxA1 expression in ERa-
Figure 6. PBX1 is a novel prognostic marker for ERa positive breast cancers. (A–B) PBX1 and FoxA1 prognostic value against metastasis-free
survival were investigated against all breast cancer subtypes through Kaplan-Meier curves derived from a meta-analysis of independent expression
profile studies from primary breast tumors available through Oncomine. (C–D) The same analysis was repeated while focusing only on the ERa-
positive patients. Statistical difference in outcomes between patients with high (top 10% expressing patients) versus low (bottom 10% expressing
patients) mRNA level was performed using Fisher exact test. (E) The number of expression signatures associated with poor-outcome defined in
primary breast tumors in independent expression profile studies that are significantly associated with PBX1-dependent or FoxA1-dependent
estrogen/17b-estradiol (E2) gene signatures is presented (p,0.01, O.R. .2). Results were generated using Oncomine concepts map analysis.
doi:10.1371/journal.pgen.1002368.g006
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metastasis-free outcome, elevated PBX1 expression has significant
prognostic potential towards metastasis. Gene signatures such as
the Oncotype DX or MammaPrint have been successfully
employed in the clinic to discriminate outcome in breast cancer
based mostly on their ability to identify specific breast cancer
subtypes [74,75]. However they do not perform as well when
restricted to ERa-positive patients [76,77]. Our study introduces
PBX1 as a potential clinical tool with additive prognostic value to
ERa. Indeed, all patients with ERa-positive metastatic breast
cancer and half or more of ERa-positive early stage breast cancers
develop resistance to endocrine therapies leading to a poor
outcome [78]. Hence, it is fascinating to speculate a role for PBX1
in the development of drug resistance in breast cancer.
Figure 7. Schematic representation of PBX1 activity in breast cancer. Schematic model depicting the relationship between PBX1, FoxA1 and
ERa in breast cancer cells stimulated or not by estrogen/17b-estradiol (E2). Both FoxA1 and PBX1 are bound to the chromatin harboring the H3K4me2
epigenetic signature. They both act independently of each other to open chromatin making specific genomic regions accessible to transcription
factors. Stimulation by E2 does not affect their chromatin occupancy but allows ERa recruitment. Importantly, sites of ERa recruitment bound by
PBX1, shared or not with FoxA1, are associated with a significant proportion of estrogen responsive genes accounting for a strong estrogen response.
doi:10.1371/journal.pgen.1002368.g007
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between distinct pioneer factors required for the implementation
of specific transcriptional response to estrogen in breast cancer and
distinguishes PBX1 as a prognostic marker.
Materials and Methods
Motif discovery
FoxA1-independent ERa binding sites across the genome were
identified by subtracting the False Discovery Rate (FDR) 20%
FoxA1 cistrome from the FDR1% estrogen-induced ERa cistrome
from MCF7 breast cancer cells. This was accomplished using the
bedfiles that specifies the genomic coordinates for the FoxA1
cistrome called by MAT available through the Cistrome website
(http://cistrome.dfci.harvard.edu/ap/) using a cutoff based on the
FDR 20% and the bedfile that specifies the genomic coordinates
for the ERa cistrome called by MAT using a cutoff based on FDR
1%. These files were loaded on the Cistrome website and the
FoxA1 bedfile was subtracted from the ERa bedfile using the
‘‘Operate on Genomic Intervals - subtract’’ [79]. To define the
proportion of the ERa cistrome overlapping or not with FoxA1
harboring the PBX1 DNA recognition motif (Transfac M01017)
we used the default settings of the ‘‘Integrative Analysis – Screen
motif’’ function available on the Cistrome website.
Correlation analysis
Expression correlation between ERa and PBX1 from the
NCI60 cancer cell panel using BioGPS (http://biogps.gnf.org).
Expression correlation analysis between ERa and PBX1 in breast
cancer cells or primary tumors was achieved using Oncomine
(https://www.oncomine.com).
Overlap analysis and genome structure correction (GSC)
Venn diagrams were generated by defining the proportion of
sites shared and unique between different bedfiles using the
functions found under ‘‘Operate on Genomic Intervals’’ within the
Cistrome website. Overlapping binding sites were defined by
having at least one base pair in common. Genome structure
correction (GSC) [80] was run to establish the significance of the
overlap between datasets. The software was run with the following
setting: (region fraction) -R=0.2, (sub-region fraction) –S=0.4
and basepair_overlap_marginal (-bm) as statistic text. P values for
results presented on Figure S6A and S6B have been corrected
using the Bonferroni post-test based on 12 comparisons.
Immunofluorescence imaging
For immunofluorescence, MCF7 cells were treated as previously
described [81]. PBX1 was stained using PBX1 monoclonal
antibody (Abnova Corporation). FoxA1 was stained using FoxA1
polyclonal antibody (Abcam). Secondary antibodies Alexa 488 and
555 were purchased from Invitrogen. Digital images were
analyzed with ImageJ (http://rsbweb.nih.gov/ij/index.html).
siRNA Transfection of MCF7 breast cancer cells
MCF7 cells were maintained in phenol red-free medium
(Invitrogen) supplemented with 10% CDT-FBS as described
previously (Lupien et al. 2008) [6] prior to transfection. Following
two days of estrogen starvation cells were transfected with siPBX1
#1 (Darmachon) or siPBX1 #2 (Invitrogen). Small-interfering
RNA against Luciferase was used as a negative control [8].
Transfection was performed using Lipofectamine2000 according
to manufacturer’s instructions (Invitrogen). For cell proliferation
assays, cell number or O.D. (450 nm) (WST-1 assay, Takara Bio
Inc) was determined every 24 h after estrogen (E2) addition
(1610
28 M final). For expression assays, RNA was extracted 3 h
following E2 stimulation.
Microarray
RNA samples from siControl or siPBX1 treated MCF7 in the
presence or absence of estrogen were hybridized on HT12 human
beads array (Illumina Inc.). Analyses were performed using BRB-
Array Tools Version 3.8.1. Raw intensity data were log2
transformed, median normalized and filtered to remove non-
detected spots as determined by Illumina Software. The normal-
ization was performed by computing a gene-by-gene difference
between each array and the median (reference) array, and
subtracting the median difference from the log intensities on that
array, so that the gene-by-gene difference between the normalized
array and the reference array is zero. Two class non-paired
comparison analyses were performed by computing a t-test for each
gene using normalized log-intensities. Differentially expressed genes
were determined at a significance level of p less than 0.01. A four
class ANOVA at p less than 0.01 was also performed to identify
genes expressed differentially across the four groups.
Hierarchical clustering was employed using a Euclidean
distance measure to generate heat maps for subsets of significant
genes using the open source software Cluster/Treeview. The data
can be accessed in GEObrowser under superSeries GSE28008
FoxA1 dependent gene-signature was obtained from previously
published microarray data [44].
ChIP and ChIP-reChIP-qPCR
ChIP qPCR was performed as described previously [82].
Antibodies against PBX1 (Abnova) FoxA1, H3K4me2 (Abcam)
and ERa (Santa cruz biotechnology) were used in these assays.
ChIP–reChIP was performed as described previously [83].
Statistically significant differences were established using a
Student’s t-test comparison for unpaired data versus an internal
negative control. Primer sequences used in this assay are found in
Table S3.
ChIP-seq
ChIP assay were conducted as described above. Library prepara-
tion for next-generation sequencing was performed according to
manufacturer’s instruction starting with 5 ng of material (Illumina
Inc.). Single paired libraries were sequenced using the GAIIx (Illumina
Inc). Over 28 and 31 million reads were generated through the GAIIx
for the PBX1 ChIP and Input samples, respectively. Of those, 88%
and 96%, respectively, were aligned to the human reference genome.
These reads were aligned using the ELAND software. The MACS
peak-calling algorithm was used to call significantly enriched peaks
using default settings (P,10
25) and specifying the peak size=200 bp.
The data is accessible on the GEObrowser (accession number:
PBX1:GSE28008 and H3K4me2:GSE31151).
FAIRE
FAIRE analysis was performed as previously described [39,84].
FAIRE-seq data were already published [44].
Transfection of MCF7 cells
MCF7 cells were maintained in DMEM (Invitrogen) supple-
mented with 10% FBS as described previously (Lupien et al. 2008)
[6] prior to transfection. MCF7 cells were transfected with the
pCMX-KDM1construct or the control empty vectors (10 mg per
well in 6 well plates) using Lipofectamine 2000 DNA transfection
reagent according to the manufacturer’s instructions (Invitrogen).
ChIP assays against PBX1 were performed 48 h post-transfection.
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Severalexpression profiles[42,63,85,86,87,88,89,90,91] compiled
in Oncomine (https://www.oncomine.com) were used to define
PBX1 and FoxA1 mRNA expression levels. ERa stratification was
based on protein levels provided in each independent expression
study employed in this analysis. Samples were ranked according to
processed probe signal provided by each independent expression
study (Max to Min) and top and bottom 10% were classified as high
and lowexpressionrespectively.Eachsamplewasthenmatchedwith
its associated outcome with a 1, 3 and 5 years follow-up provided by
each independent study (metastasis-free survival: alive or dead).
Statistical analyses were performed using Fisher exact test.
Transcriptome-based outcome analysis
PBX1-dependent or FoxA1-dependent estrogen (E2) upregu-
lated gene signatures [44] were analyzed against several expression
profiles previously shown to be significantly associated with breast
cancer outcome using Oncomine. [86,87,88,90,92,93,94,95,96,97,
98,99,100,101,102,103] Significant association was established at
a pValue of at least ,0.01 and an Odds Ratio .2.
Supporting Information
Figure S1 PBX1 is the main PBX family member expressed in
MCF7. (A) The proportion of AR binding sites harboring the PBX1
matrix (Transfac: M01017) is presented. Percentages are calculated
based on the previously published 5077 AR binding sites from LNCaP
cells treated with DHT for 4 hours (Brown lab) B) PBX family member
expression in MCF7 was assessed by RT-qPCR. Data are expressed as
percentage of PBX1 in mock induced (O) MCF7 cells. Expression
under estrogen/17b-estradiol (E2) is also presented. (p***,0.001).
(TIF)
Figure S2 PBX1 suppresses estrogen-induced proliferation. (A)
MCF7 cells were stimulated with estrogen/17b-estradiol (E2) or
control (O) with or without PBX1 silencing via siRNA and cell
were counted after 2 days and compared to control (siCTRL)
(p*,0.05, **,0.01) (B) Comparison of cell number in MCF7 cells
treated with siPBX1 vs siCTR in a estrogen-deprived media (O).
(TIF)
Figure S3 PBX1 and FoxA1 partially co-localize in MCF7 cells
nucleus. (A) Protein localization was analyzed after PBX1 and
FoxA1 staining via digital imaging. (B) Same as A but with the
added Z-axis represent staining intensity.
(TIF)
Figure S4 ERa recruitment is specifically disrupted at PBX1
bound sites. (A) CEAS analysis demonstrate genomic distribution
of PBX1 binding in MCF7 breast cancer cells (B) ChIP-qPCR
assays against PBX1 were conducted to validate PBX1 ChIP-seq
results in MCF7 breast cancer cells treated with estrogen/17b-
estradiol (E2) or control (O). (C) ChIP-qPCR assays in MCF7 cells
depleted of estrogen against PBX1 demonstrate that it is not
present at the tested ERa binding sites while it is efficiently
detected at the positive control (pos. CTRL) site.
(TIF)
Figure S5 ChIP-seq tracks. Raw massively parallel sequencing
(WIG lines) and called peaks (BED lines) derived signal for ERa
(estrogen stimulated), PBX1 (full media), FoxA1 (full media),
FAIRE (untreated) and H3K4me2 (untreated) signal from MCF7
at representative genomic locations were obtained using the
integrated genomic viewer (IGV 2.0). Boxes were used to
underscore the primers used in this study.
(TIF)
Figure S6 ChIP-seq tracks. Raw massively parallel sequencing
(WIG lines) and called peaks (BED lines) derived signal for ERa
(estrogen stimulated), PBX1 (full media), FoxA1 (full media),
FAIRE (untreated) and H3K4me2 (untreated) signal from MCF7
at representative genomic locations were obtained using the
integrated genomic viewer (IGV 2.0). Boxes were used to
underscore the primers used in this study.
(TIF)
Figure S7 ChIP-seq tracks. Raw massively parallel sequencing
(WIG lines) and called peaks (BED lines) derived signal for ERa
(estrogen stimulated), PBX1 (full media), FoxA1 (full media),
FAIRE (untreated) and H3K4me2 (untreated) signal from MCF7
at representative genomic locations were obtained using the
integrated genomic viewer (IGV 2.0). Boxes were used to
underscore the primers used in this study.
(TIF)
Figure S8 ChIP-seq tracks. Raw massively parallel sequencing
(WIG lines) and called peaks (BED lines) derived signal for ERa
(estrogen stimulated), PBX1 (full media), FoxA1 (full media),
FAIRE (untreated) and H3K4me2 (untreated) signal from MCF7
at representative genomic locations were obtained using the
integrated genomic viewer (IGV 2.0). Boxes were used to
underscore the primers used in this study.
(TIF)
Figure S9 Cistromes intersections. GSC analysis of various
cistromes (ERa, FoxA1, and AR) against PBX1.
(TIF)
Figure S10 Cistromes intersections. GSC analysis of PBX1
cistrome against ERa, FoxA1 and AR cistromes.
(TIF)
Figure S11 PBX1 and FoxA1 co-localize on the chromatin.
ChIP-reChIP assay demonstrates that PBX1 and FoxA1 can co-
bind the same DNA sites in MCF7 cells in absence of estrogen (O).
Matched IgG were used in the reChIP as negative control.
(TIF)
Figure S12 Expression profile defines the PBX1-dependent
estrogen regulated genes in MCF7 breast cancer cells. Heatmap
displayed as a ratio between estrogen/17b-estradiol (E2) and
control (O) treated cells in MCF7 breast cancer cells depleted or
not of PBX1 by siRNA. Yellow relates to E2 induction while blue
relates to E2 repression.
(TIF)
Figure S13 PBX1 and FoxA1 silencing selectively impairs E2
response. Histogram of the data presented in Figure 3D. Asterisks
represent significant difference determined by one-way ANOVA
analysis vs. siCTRL (p,0.05).
(TIF)
Figure S14 PBX1 silencing removes PBX1 from the chromatin.
(A) Percentage of number of sites overlapping with peaks of
FAIRE signal called by the MACS peak-calling algorithm. This
demonstrates that FAIRE is significantly associated with PBX1-
FoxA1 shared sites versus PBX1 of FoxA1 unique sites. (B) MCF7
cells were cultured in estrogen-free media and treated with
siPBX1. ChIP-qPCR assays against PBX1 were performed in
siPBX1 and siCTRL transfected cells. Values are expressed as
percentage of reduction of PBX1 presence on the chromatin in
siPBX1 versus siCTRL transfected cells (p*,0.05).
(TIF)
Figure S15 PBX1 silencing does not alter the epigenetic
signature H3K4me2. (A) Depleting MCF7 cells of PBX1 via
PBX1 Guides ERa Signaling in Breast Cancer
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determined by ChIP-qPCR in absence of estrogen. Relative fold
enrichment is expressed as fold over negative internal control. (B)
PBX1 silencing does not alter the expression of the H3K4me2
specific de-methylases KDM1 regardless of estrogen (E2) or
control (O) treatment.
(TIF)
Figure S16 PBX1 prognostic potential in breast cancer. (A–B)
Kaplan-Meier curve were generated using KMplotter splitting
patients using the upper quartile. ERa and FoxA1can significantly
predict metastasis development in breast cancer subtype. Bees-
warm graphs are used to plot probe distribution. (C–D) Kaplan-
Meier curve were generated as in A–B limiting the analysis to
ERa-positive breast cancer subtype as defined by pathological
staining. PBX1 can significantly predict metastasis development in
ERa-positive breast cancer subtype.
(TIF)
Figure S17 Expression levels for FoxA1 and PBX1 across
primary breast tumors. The average level of FoxA1 (left panel) and
PBX1 (right panel) mRNA levels in primary breast tumors
compiled for to generate the Kaplan-Meier curves (Figure 6) are
presented. The difference in FoxA1 mRNA expression between
the high and low FoxA1 expressers is greatest across all breast
cancer subtypes as opposed to the ERa-positive breast cancer
subtype. The difference in PBX1 mRNA expression between the
high and low PBX1 expressers remains the same when assessed
across all breast cancer subtypes or the ERa-positive breast cancer
subtype.
(TIF)
Table S1 Gene coexpressed in the NCI60 cancer cell lines with
PBX1.
(XLS)
Table S2 Microarray analysis of genes significantly changed
between control and estradiol stimulation (pvalue,0.01).
(XLS)
Table S3 List of primers used in the study.
(XLS)
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